Curated News
By: NewsRamp Editorial Staff
June 12, 2025
Scinai Immunotherapeutics to Showcase Milestones at BIO 2025
TLDR
- Scinai Immunotherapeutics secures $1.38M funding and aims for $2M CDMO revenue in 2025, offering investors a growth opportunity in biopharmaceuticals.
- Scinai Immunotherapeutics will detail its CDMO growth and nanobody pipeline progress at BIO International Convention 2025, following a $1.38M funding boost.
- Scinai Immunotherapeutics advances NanoAbs targeting unmet medical needs, contributing to better treatments for inflammation and immunology diseases.
- Discover how Scinai Immunotherapeutics is innovating in biopharmaceuticals with its NanoAbs and CDMO services at BIO International Convention 2025.
Impact - Why it Matters
This news is significant for investors and stakeholders in the biopharmaceutical industry, as it highlights Scinai Immunotherapeutics' progress and financial health. The company's participation in the BIO International Convention 2025 and its recent funding achievement underscore its potential for growth and innovation in developing treatments for diseases with unmet medical needs. Additionally, Scinai's CDMO business growth and revenue targets provide a glimpse into the company's strategic direction and its role in supporting early-stage biotech companies, making it a key player to watch in the evolving biotech landscape.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company, has announced that its CEO, Amir Reichman, will be participating in the BIO International Convention 2025 in Boston. The company plans to showcase its recent achievements, including significant growth in its CDMO business and advancements in its nanobody pipeline. Notably, Scinai has secured $1.38 million in funding through a Standby Equity Purchase Agreement with Yorkville Advisors, enhancing its capital without causing additional dilution. The company is optimistic about its financial outlook, reaffirming its 2025 CDMO revenue guidance of $2 million and aiming for breakeven by 2026. For more details, visit the full press release.
Scinai operates two main business units: one dedicated to developing innovative NanoAbs for inflammation and immunology diseases, and the other offering comprehensive CDMO services to early-stage biotech companies. Discover more about their groundbreaking work at www.Scinai.com. InvestorWire, a key player in financial communications, highlights Scinai's latest updates, emphasizing the company's strategic positioning and growth potential in the biopharmaceutical sector.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Immunotherapeutics to Showcase Milestones at BIO 2025
